Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
Compound profiling in drug resistant cell lines
The epidermal growth factor receptor (EGFR) kinase inhibitor osimertinib is a first-line treatment of non-small cell lung cancer with oncogenic driver mutations in EGFR, […]
New Oncolines case study presented at ENA 2024 conference in Barcelona
Oncolines will present three posters at the EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics conference that will be held in Barcelona (Spain) from October […]
Oncolines launches assay for long COVID and cancer immunotherapy target IDO2
The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 2 (IDO2) is a potential therapeutic target for long COVID and cancer immunotherapy. IDO2 has 44% amino acid identity […]
Oncolines offers cell toxicity as an alternative readout for 102 cancer cell panel profiling studies
Oncolines® profiling is the parallel testing of compounds, either small molecules or biologics, on a large panel of human cancer cell lines. We use […]
Premium Benefits of Oncolines Precision Medicine Services: Cell-Based Assays, Drug Combinations, High-Throughput Screening